Head and Neck Cancer Companies

Latest Head and Neck Cancer Companies Updates:

Merck & Co.'s Keytruda (pembrolizumab) Approval: This immunotherapy drug received FDA approval for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with PD-L1 expression, offering a promising new option for patients.

Bristol Myers Squibb's Opdivo (nivolumab) Combo Therapy: This drug, in combination with cetuximab, demonstrated promising results in a Phase 3 trial for treating recurrent or metastatic HNSCC, potentially paving the way for more effective combination therapies.

AstraZeneca's Lynparza (olaparib) for BRCA Mutations: This drug received FDA approval for the maintenance treatment of adult patients with locally advanced or metastatic HNSCC harboring BRCA gene mutations, offering a targeted therapy option for a specific patient subgroup.

Personalis, Inc.'s NGS Companion Diagnostic: This company's next-generation sequencing (NGS) test was granted FDA approval as a companion diagnostic for Lynparza, helping identify patients who may benefit most from this targeted therapy.

List of Head and Neck Cancer Key companies in the market:

• Bayer Healthcare AG


• Boston Biomedical, Inc.


• Bristol-Myers Squibb Company


• Astellas Pharma Inc.


• AbbVie Inc.


• AstraZeneca Plc.


• Acceleron Pharma Inc.


• DentalEZ, Inc.


• Koninklijke Philips N.V.


• Siemens Healthcare Private Limited


• AB Sciences